规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
Akt1 (IC50 = 5 nM); Akt3 (IC50 = 8 nM); Akt2 (IC50 = 18 nM); PKA (IC50 = 3100 nM)
|
---|---|
体外研究 (In Vitro) |
当针对大量 230 种激酶(PRKG1α、PRKG1β 和 p70S6K,IC50 值分别为 98 nM、69 nM 和 860 nM)进行测试时,GDC-0068 在 1 μM 浓度下仅抑制 3 种激酶 >70%。 GDC-0068 的 IC50 为 3.1 μM,对 Akt 的选择性是 PKA 的 100 倍以上。 GDC-0068 处理可抑制 LNCaP、PC3 和 BT474M1 细胞中 Akt 底物 PRAS40 的磷酸化,IC50 值分别为 157 nM、197 nM 和 208 nM。此外,GDC-0068 选择性抑制肿瘤抑制因子 PTEN 缺陷、PIK3CA 致癌突变和 HER2 扩增的 Akt 信号驱动癌细胞系,其中 HER2+ 和 Luminal 亚型的效果最强。 [1-4]
|
体内研究 (In Vivo) |
GDC-0068 口服给药会导致 PC3 前列腺肿瘤异种移植模型中 p-PRAS40 下调。 BT474-Tr 异种移植物中的 GDC-0068 治疗可降低 pS6 和 peIF4G 水平,将 FOXO3a 重新定位到细胞核,并导致 HER3 和 pERK 的反馈上调。在许多异种移植肿瘤模型中,包括 PTEN 缺陷型前列腺癌模型 LNCaP 和 PC3、PIK3CA H1047R 突变乳腺癌模型 KPL-4 和 MCF7-neo/HER2 肿瘤模型,GDC-0068 的给药表现出强大的抗肿瘤功效。 1-4]
|
动物实验 |
Female nude mice bearing LNCaP, PC3, KPL-4, or MCF7 tumor xenografts
~100 mg/kg/day Orally |
参考文献 |
分子式 |
C24H32CLN5O2
|
---|---|
分子量 |
457.9962
|
精确质量 |
457.22445
|
元素分析 |
C, 62.94; H, 7.04; Cl, 7.74; N, 15.29; O, 6.99
|
CAS号 |
1001264-89-6
|
相关CAS号 |
Ipatasertib dihydrochloride;1396257-94-5
|
外观&性状 |
Solid powder
|
SMILES |
C[C@@H]1C[C@H](C2=C1C(=NC=N2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)C4=CC=C(C=C4)Cl)O
|
InChi Key |
GRZXWCHAXNAUHY-NSISKUIASA-N
|
InChi Code |
InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
|
化学名 |
(2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one
|
别名 |
GDC0068; GDC 0068; GDC-0068; RG-7440; RG 7440; RG7440; Ipatasertib
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~92 mg/mL (~200.9 mM)
Water: <1 mg/mL Ethanol: ~92 mg/mL (~200.9 mM) |
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5% DMSO+40% PEG 300+5%Tween80+ 50%ddH2O: 92mg/ml Solubility in Formulation 5: 10 mg/mL (21.83 mM) in 0.5% MC 0.5% Tween-80 (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1834 mL | 10.9170 mL | 21.8341 mL | |
5 mM | 0.4367 mL | 2.1834 mL | 4.3668 mL | |
10 mM | 0.2183 mL | 1.0917 mL | 2.1834 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04464174 | Active Recruiting |
Drug: Ipatasertib | Triple Negative Breast Cancer | MedSIR | October 8, 2020 | Phase 2 |
NCT03072238 | Active Recruiting |
Drug: Ipatasertib Drug: Placebo |
Metastatic Prostate Cancer | Hoffmann-La Roche | June 30, 2017 | Phase 3 |
NCT03395899 | Active Recruiting |
Drug: Ipatasertib Drug: Bevacizumab P |
Breast Cancer Estrogen Receptor-positive Breast Cancer |
Queen Mary University of London | December 21, 2017 | Phase 2 |
NCT03853707 | Active Recruiting |
Drug: Ipatasertib Drug: Paclitaxel |
Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Triple-Negative Breast Carcinoma |
City of Hope Medical Center | March 4, 2019 | Phase 1 Phase 3 |
NCT04060862 | Active Recruiting |
Drug: Ipatasertib Drug: Placebo |
Breast Cancer | Hoffmann-La Roche | November 15, 2019 | Phase 3 |
Dose-dependent effect of GDC-0068 on Akt pathway biomarkers. Clin Canc Res 2013, 19:1760–1772. td> |
Single agent efficacy of GDC-0068 in human tumor xenograft models. td> |
Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of GDC-0068 in xenograft models. td> |